Medullary thyroid carcinoma, 155240, Autosomal dominant (Multiple endocrine neoplasia type 2) (MLPA)
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000582065.1
- Last updated: 2020-05-19
- Annual Review past due read more
- Test version history
- 582065.1, last updated: 2020-05-19
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Familial medullary thyroid carcinoma
Offered by Intergen
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.Medullary thyroid carcinoma, 155240, Autosomal dominant (Multiple endocrine neoplasia type 2) (MLPA)
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Diagnosis
Click Indication tab for more information.
Not provided
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- DDeletion/duplication analysis
- Multiplex Ligation-dependent Probe Amplification (MLPA)
Not provided
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Not provided
- NCI PDQ, Endocrine and Neuroendocrine Neoplasia geneticsGenetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version
- NCI PDQ, Cancer Genetics CounselingCancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version
- NICE, 2022UK NICE Guideline NG230, Thyroid cancer: assessment and management
- EuroGenetest, 2011Clinical utility gene card for: multiple endocrine neoplasia type 2.
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.